nodes	percent_of_prediction	percent_of_DWPC	metapath
Anagrelide—PDE3A—hypertension	0.468	1	CbGaD
Anagrelide—CYP1A2—Guanabenz—hypertension	0.0334	0.136	CbGbCtD
Anagrelide—CYP1A2—Triamterene—hypertension	0.0334	0.136	CbGbCtD
Anagrelide—CYP1A2—Betaxolol—hypertension	0.0277	0.113	CbGbCtD
Anagrelide—CYP1A2—Nisoldipine—hypertension	0.0244	0.0991	CbGbCtD
Anagrelide—CYP1A2—Irbesartan—hypertension	0.0192	0.078	CbGbCtD
Anagrelide—CYP1A2—Amlodipine—hypertension	0.0188	0.0765	CbGbCtD
Anagrelide—CYP1A2—Nifedipine—hypertension	0.0175	0.0713	CbGbCtD
Anagrelide—CYP1A2—Carvedilol—hypertension	0.0173	0.0702	CbGbCtD
Anagrelide—CYP1A2—Propranolol—hypertension	0.0159	0.0646	CbGbCtD
Anagrelide—CYP1A2—Clonidine—hypertension	0.0152	0.0616	CbGbCtD
Anagrelide—CYP1A2—Losartan—hypertension	0.0124	0.0503	CbGbCtD
Anagrelide—CYP1A2—Verapamil—hypertension	0.0109	0.0443	CbGbCtD
Anagrelide—CYP1A2—urine—hypertension	0.000515	0.17	CbGeAlD
Anagrelide—PDE3A—cardiac ventricle—hypertension	0.000454	0.15	CbGeAlD
Anagrelide—PDE3A—myocardium—hypertension	0.000427	0.141	CbGeAlD
Anagrelide—PDE3A—heart—hypertension	0.000298	0.0985	CbGeAlD
Anagrelide—PDE3A—smooth muscle tissue—hypertension	0.000296	0.0977	CbGeAlD
Anagrelide—PDE3A—cardiovascular system—hypertension	0.000281	0.0929	CbGeAlD
Anagrelide—PDE3A—cardiac atrium—hypertension	0.000255	0.0842	CbGeAlD
Anagrelide—PDE3A—adrenal gland—hypertension	0.000223	0.0735	CbGeAlD
Anagrelide—PDE3A—endocrine gland—hypertension	0.000193	0.0637	CbGeAlD
Anagrelide—CYP1A2—endocrine gland—hypertension	8.55e-05	0.0282	CbGeAlD
Anagrelide—Abdominal pain—Perindopril—hypertension	2.18e-05	0.000102	CcSEcCtD
Anagrelide—Body temperature increased—Perindopril—hypertension	2.18e-05	0.000102	CcSEcCtD
Anagrelide—Palpitations—Lisinopril—hypertension	2.18e-05	0.000102	CcSEcCtD
Anagrelide—Diarrhoea—Olmesartan—hypertension	2.18e-05	0.000102	CcSEcCtD
Anagrelide—Headache—Eplerenone—hypertension	2.18e-05	0.000102	CcSEcCtD
Anagrelide—Rash—Nifedipine—hypertension	2.17e-05	0.000102	CcSEcCtD
Anagrelide—Nervous system disorder—Ramipril—hypertension	2.17e-05	0.000102	CcSEcCtD
Anagrelide—Dermatitis—Nifedipine—hypertension	2.17e-05	0.000102	CcSEcCtD
Anagrelide—Abdominal pain—Irbesartan—hypertension	2.17e-05	0.000102	CcSEcCtD
Anagrelide—Body temperature increased—Irbesartan—hypertension	2.17e-05	0.000102	CcSEcCtD
Anagrelide—Thrombocytopenia—Ramipril—hypertension	2.17e-05	0.000102	CcSEcCtD
Anagrelide—Oedema—Timolol—hypertension	2.17e-05	0.000102	CcSEcCtD
Anagrelide—Loss of consciousness—Lisinopril—hypertension	2.16e-05	0.000102	CcSEcCtD
Anagrelide—Rash—Verapamil—hypertension	2.16e-05	0.000102	CcSEcCtD
Anagrelide—Urticaria—Hydrochlorothiazide—hypertension	2.16e-05	0.000102	CcSEcCtD
Anagrelide—Tachycardia—Ramipril—hypertension	2.16e-05	0.000102	CcSEcCtD
Anagrelide—Dermatitis—Verapamil—hypertension	2.16e-05	0.000102	CcSEcCtD
Anagrelide—Headache—Nifedipine—hypertension	2.16e-05	0.000102	CcSEcCtD
Anagrelide—Pruritus—Clonidine—hypertension	2.16e-05	0.000101	CcSEcCtD
Anagrelide—Abdominal pain—Hydrochlorothiazide—hypertension	2.15e-05	0.000101	CcSEcCtD
Anagrelide—Body temperature increased—Hydrochlorothiazide—hypertension	2.15e-05	0.000101	CcSEcCtD
Anagrelide—Skin disorder—Ramipril—hypertension	2.15e-05	0.000101	CcSEcCtD
Anagrelide—Infection—Timolol—hypertension	2.15e-05	0.000101	CcSEcCtD
Anagrelide—Headache—Verapamil—hypertension	2.15e-05	0.000101	CcSEcCtD
Anagrelide—Cough—Lisinopril—hypertension	2.15e-05	0.000101	CcSEcCtD
Anagrelide—Nausea—Diltiazem—hypertension	2.15e-05	0.000101	CcSEcCtD
Anagrelide—Nausea—Indapamide—hypertension	2.15e-05	0.000101	CcSEcCtD
Anagrelide—Hyperhidrosis—Ramipril—hypertension	2.14e-05	0.000101	CcSEcCtD
Anagrelide—Asthenia—Trandolapril—hypertension	2.13e-05	0.0001	CcSEcCtD
Anagrelide—Shock—Timolol—hypertension	2.13e-05	0.0001	CcSEcCtD
Anagrelide—Feeling abnormal—Losartan—hypertension	2.13e-05	0.0001	CcSEcCtD
Anagrelide—Urticaria—Furosemide—hypertension	2.13e-05	0.0001	CcSEcCtD
Anagrelide—Nervous system disorder—Timolol—hypertension	2.12e-05	9.99e-05	CcSEcCtD
Anagrelide—Nausea—Carvedilol—hypertension	2.12e-05	9.99e-05	CcSEcCtD
Anagrelide—Asthenia—Enalapril—hypertension	2.12e-05	9.98e-05	CcSEcCtD
Anagrelide—Abdominal pain—Furosemide—hypertension	2.12e-05	9.96e-05	CcSEcCtD
Anagrelide—Body temperature increased—Furosemide—hypertension	2.12e-05	9.96e-05	CcSEcCtD
Anagrelide—Gastrointestinal pain—Losartan—hypertension	2.11e-05	9.94e-05	CcSEcCtD
Anagrelide—Dizziness—Valsartan—hypertension	2.11e-05	9.94e-05	CcSEcCtD
Anagrelide—Anorexia—Ramipril—hypertension	2.11e-05	9.93e-05	CcSEcCtD
Anagrelide—Urticaria—Betaxolol—hypertension	2.11e-05	9.91e-05	CcSEcCtD
Anagrelide—Skin disorder—Timolol—hypertension	2.1e-05	9.9e-05	CcSEcCtD
Anagrelide—Dizziness—Olmesartan—hypertension	2.1e-05	9.89e-05	CcSEcCtD
Anagrelide—Pruritus—Trandolapril—hypertension	2.1e-05	9.88e-05	CcSEcCtD
Anagrelide—Nausea—Doxazosin—hypertension	2.1e-05	9.88e-05	CcSEcCtD
Anagrelide—Chest pain—Lisinopril—hypertension	2.1e-05	9.86e-05	CcSEcCtD
Anagrelide—Arthralgia—Lisinopril—hypertension	2.1e-05	9.86e-05	CcSEcCtD
Anagrelide—Myalgia—Lisinopril—hypertension	2.1e-05	9.86e-05	CcSEcCtD
Anagrelide—Body temperature increased—Betaxolol—hypertension	2.1e-05	9.86e-05	CcSEcCtD
Anagrelide—Hyperhidrosis—Timolol—hypertension	2.09e-05	9.85e-05	CcSEcCtD
Anagrelide—Asthenia—Telmisartan—hypertension	2.09e-05	9.85e-05	CcSEcCtD
Anagrelide—Pruritus—Enalapril—hypertension	2.09e-05	9.85e-05	CcSEcCtD
Anagrelide—Diarrhoea—Clonidine—hypertension	2.08e-05	9.8e-05	CcSEcCtD
Anagrelide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—hypertension	2.08e-05	9.79e-05	CcSEcCtD
Anagrelide—Nausea—Fosinopril—hypertension	2.08e-05	9.76e-05	CcSEcCtD
Anagrelide—Discomfort—Lisinopril—hypertension	2.07e-05	9.74e-05	CcSEcCtD
Anagrelide—Hypotension—Ramipril—hypertension	2.07e-05	9.74e-05	CcSEcCtD
Anagrelide—Anorexia—Timolol—hypertension	2.07e-05	9.71e-05	CcSEcCtD
Anagrelide—Pruritus—Telmisartan—hypertension	2.06e-05	9.71e-05	CcSEcCtD
Anagrelide—Nausea—Eplerenone—hypertension	2.06e-05	9.7e-05	CcSEcCtD
Anagrelide—Urticaria—Losartan—hypertension	2.05e-05	9.66e-05	CcSEcCtD
Anagrelide—Dry mouth—Lisinopril—hypertension	2.05e-05	9.64e-05	CcSEcCtD
Anagrelide—Nausea—Nifedipine—hypertension	2.05e-05	9.63e-05	CcSEcCtD
Anagrelide—Body temperature increased—Losartan—hypertension	2.04e-05	9.61e-05	CcSEcCtD
Anagrelide—Abdominal pain—Losartan—hypertension	2.04e-05	9.61e-05	CcSEcCtD
Anagrelide—Nausea—Verapamil—hypertension	2.04e-05	9.59e-05	CcSEcCtD
Anagrelide—Asthenia—Captopril—hypertension	2.04e-05	9.58e-05	CcSEcCtD
Anagrelide—Diarrhoea—Trandolapril—hypertension	2.03e-05	9.56e-05	CcSEcCtD
Anagrelide—Vomiting—Valsartan—hypertension	2.03e-05	9.56e-05	CcSEcCtD
Anagrelide—Confusional state—Lisinopril—hypertension	2.03e-05	9.53e-05	CcSEcCtD
Anagrelide—Diarrhoea—Enalapril—hypertension	2.02e-05	9.52e-05	CcSEcCtD
Anagrelide—Hypotension—Timolol—hypertension	2.02e-05	9.52e-05	CcSEcCtD
Anagrelide—Vomiting—Olmesartan—hypertension	2.02e-05	9.51e-05	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Ramipril—hypertension	2.02e-05	9.5e-05	CcSEcCtD
Anagrelide—Rash—Valsartan—hypertension	2.01e-05	9.48e-05	CcSEcCtD
Anagrelide—Dizziness—Clonidine—hypertension	2.01e-05	9.47e-05	CcSEcCtD
Anagrelide—Dermatitis—Valsartan—hypertension	2.01e-05	9.47e-05	CcSEcCtD
Anagrelide—Oedema—Lisinopril—hypertension	2.01e-05	9.45e-05	CcSEcCtD
Anagrelide—Pruritus—Captopril—hypertension	2.01e-05	9.44e-05	CcSEcCtD
Anagrelide—Rash—Olmesartan—hypertension	2.01e-05	9.43e-05	CcSEcCtD
Anagrelide—Insomnia—Ramipril—hypertension	2e-05	9.43e-05	CcSEcCtD
Anagrelide—Dermatitis—Olmesartan—hypertension	2e-05	9.42e-05	CcSEcCtD
Anagrelide—Headache—Valsartan—hypertension	2e-05	9.42e-05	CcSEcCtD
Anagrelide—Diarrhoea—Telmisartan—hypertension	2e-05	9.39e-05	CcSEcCtD
Anagrelide—Infection—Lisinopril—hypertension	2e-05	9.39e-05	CcSEcCtD
Anagrelide—Headache—Olmesartan—hypertension	1.99e-05	9.37e-05	CcSEcCtD
Anagrelide—Paraesthesia—Ramipril—hypertension	1.99e-05	9.36e-05	CcSEcCtD
Anagrelide—Shock—Lisinopril—hypertension	1.98e-05	9.3e-05	CcSEcCtD
Anagrelide—Asthenia—Perindopril—hypertension	1.98e-05	9.3e-05	CcSEcCtD
Anagrelide—Dyspnoea—Ramipril—hypertension	1.98e-05	9.29e-05	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Timolol—hypertension	1.97e-05	9.28e-05	CcSEcCtD
Anagrelide—Asthenia—Irbesartan—hypertension	1.97e-05	9.27e-05	CcSEcCtD
Anagrelide—Somnolence—Ramipril—hypertension	1.97e-05	9.27e-05	CcSEcCtD
Anagrelide—Thrombocytopenia—Lisinopril—hypertension	1.97e-05	9.25e-05	CcSEcCtD
Anagrelide—Dizziness—Trandolapril—hypertension	1.96e-05	9.24e-05	CcSEcCtD
Anagrelide—Tachycardia—Lisinopril—hypertension	1.96e-05	9.22e-05	CcSEcCtD
Anagrelide—Insomnia—Timolol—hypertension	1.96e-05	9.22e-05	CcSEcCtD
Anagrelide—Dizziness—Enalapril—hypertension	1.96e-05	9.2e-05	CcSEcCtD
Anagrelide—Asthenia—Hydrochlorothiazide—hypertension	1.95e-05	9.19e-05	CcSEcCtD
Anagrelide—Skin disorder—Lisinopril—hypertension	1.95e-05	9.18e-05	CcSEcCtD
Anagrelide—Dyspepsia—Ramipril—hypertension	1.95e-05	9.17e-05	CcSEcCtD
Anagrelide—Pruritus—Perindopril—hypertension	1.95e-05	9.17e-05	CcSEcCtD
Anagrelide—Paraesthesia—Timolol—hypertension	1.95e-05	9.15e-05	CcSEcCtD
Anagrelide—Pruritus—Irbesartan—hypertension	1.94e-05	9.14e-05	CcSEcCtD
Anagrelide—Hyperhidrosis—Lisinopril—hypertension	1.94e-05	9.14e-05	CcSEcCtD
Anagrelide—Diarrhoea—Captopril—hypertension	1.94e-05	9.13e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B1—hypertension	1.94e-05	0.000275	CbGpPWpGaD
Anagrelide—Vomiting—Clonidine—hypertension	1.94e-05	9.11e-05	CcSEcCtD
Anagrelide—Dyspnoea—Timolol—hypertension	1.93e-05	9.08e-05	CcSEcCtD
Anagrelide—Dizziness—Telmisartan—hypertension	1.93e-05	9.08e-05	CcSEcCtD
Anagrelide—Pruritus—Hydrochlorothiazide—hypertension	1.93e-05	9.06e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—GCG—hypertension	1.93e-05	0.000273	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTPN1—hypertension	1.93e-05	0.000273	CbGpPWpGaD
Anagrelide—Decreased appetite—Ramipril—hypertension	1.93e-05	9.06e-05	CcSEcCtD
Anagrelide—Somnolence—Timolol—hypertension	1.93e-05	9.06e-05	CcSEcCtD
Anagrelide—Asthenia—Furosemide—hypertension	1.92e-05	9.04e-05	CcSEcCtD
Anagrelide—Rash—Clonidine—hypertension	1.92e-05	9.03e-05	CcSEcCtD
Anagrelide—Dermatitis—Clonidine—hypertension	1.92e-05	9.02e-05	CcSEcCtD
Anagrelide—Anorexia—Lisinopril—hypertension	1.92e-05	9.01e-05	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Ramipril—hypertension	1.91e-05	9e-05	CcSEcCtD
Anagrelide—Fatigue—Ramipril—hypertension	1.91e-05	8.99e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—FADS1—hypertension	1.91e-05	0.000271	CbGpPWpGaD
Anagrelide—Headache—Clonidine—hypertension	1.91e-05	8.97e-05	CcSEcCtD
Anagrelide—Dyspepsia—Timolol—hypertension	1.91e-05	8.97e-05	CcSEcCtD
Anagrelide—Asthenia—Betaxolol—hypertension	1.9e-05	8.95e-05	CcSEcCtD
Anagrelide—Nausea—Valsartan—hypertension	1.9e-05	8.93e-05	CcSEcCtD
Anagrelide—Pruritus—Furosemide—hypertension	1.9e-05	8.91e-05	CcSEcCtD
Anagrelide—Constipation—Ramipril—hypertension	1.9e-05	8.91e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—KL—hypertension	1.89e-05	0.000268	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOTCH2—hypertension	1.89e-05	0.000268	CbGpPWpGaD
Anagrelide—Nausea—Olmesartan—hypertension	1.89e-05	8.88e-05	CcSEcCtD
Anagrelide—Vomiting—Trandolapril—hypertension	1.89e-05	8.88e-05	CcSEcCtD
Anagrelide—Diarrhoea—Perindopril—hypertension	1.89e-05	8.87e-05	CcSEcCtD
Anagrelide—Decreased appetite—Timolol—hypertension	1.88e-05	8.86e-05	CcSEcCtD
Anagrelide—Vomiting—Enalapril—hypertension	1.88e-05	8.85e-05	CcSEcCtD
Anagrelide—Diarrhoea—Irbesartan—hypertension	1.88e-05	8.84e-05	CcSEcCtD
Anagrelide—Hypotension—Lisinopril—hypertension	1.88e-05	8.83e-05	CcSEcCtD
Anagrelide—Dizziness—Captopril—hypertension	1.88e-05	8.83e-05	CcSEcCtD
Anagrelide—Pruritus—Betaxolol—hypertension	1.88e-05	8.82e-05	CcSEcCtD
Anagrelide—Rash—Trandolapril—hypertension	1.87e-05	8.81e-05	CcSEcCtD
Anagrelide—Dermatitis—Trandolapril—hypertension	1.87e-05	8.8e-05	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Timolol—hypertension	1.87e-05	8.8e-05	CcSEcCtD
Anagrelide—Fatigue—Timolol—hypertension	1.87e-05	8.78e-05	CcSEcCtD
Anagrelide—Rash—Enalapril—hypertension	1.87e-05	8.77e-05	CcSEcCtD
Anagrelide—Dermatitis—Enalapril—hypertension	1.86e-05	8.77e-05	CcSEcCtD
Anagrelide—Diarrhoea—Hydrochlorothiazide—hypertension	1.86e-05	8.76e-05	CcSEcCtD
Anagrelide—Headache—Trandolapril—hypertension	1.86e-05	8.75e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—TBXAS1—hypertension	1.86e-05	0.000263	CbGpPWpGaD
Anagrelide—Vomiting—Telmisartan—hypertension	1.86e-05	8.73e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ITGAV—hypertension	1.85e-05	0.000263	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NGFR—hypertension	1.85e-05	0.000263	CbGpPWpGaD
Anagrelide—Asthenia—Losartan—hypertension	1.85e-05	8.72e-05	CcSEcCtD
Anagrelide—Headache—Enalapril—hypertension	1.85e-05	8.72e-05	CcSEcCtD
Anagrelide—Pain—Timolol—hypertension	1.85e-05	8.71e-05	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—TGFB1—hypertension	1.85e-05	0.000262	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KNG1—hypertension	1.85e-05	0.000262	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—POMC—hypertension	1.84e-05	0.000261	CbGpPWpGaD
Anagrelide—Rash—Telmisartan—hypertension	1.84e-05	8.65e-05	CcSEcCtD
Anagrelide—Dermatitis—Telmisartan—hypertension	1.84e-05	8.65e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PRL—hypertension	1.84e-05	0.00026	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AGTR1—hypertension	1.84e-05	0.00026	CbGpPWpGaD
Anagrelide—Diarrhoea—Furosemide—hypertension	1.83e-05	8.62e-05	CcSEcCtD
Anagrelide—Musculoskeletal discomfort—Lisinopril—hypertension	1.83e-05	8.61e-05	CcSEcCtD
Anagrelide—Pruritus—Losartan—hypertension	1.83e-05	8.6e-05	CcSEcCtD
Anagrelide—Headache—Telmisartan—hypertension	1.83e-05	8.6e-05	CcSEcCtD
Anagrelide—Feeling abnormal—Ramipril—hypertension	1.83e-05	8.59e-05	CcSEcCtD
Anagrelide—Dizziness—Perindopril—hypertension	1.82e-05	8.57e-05	CcSEcCtD
Anagrelide—Insomnia—Lisinopril—hypertension	1.82e-05	8.55e-05	CcSEcCtD
Anagrelide—Dizziness—Irbesartan—hypertension	1.82e-05	8.54e-05	CcSEcCtD
Anagrelide—Diarrhoea—Betaxolol—hypertension	1.81e-05	8.53e-05	CcSEcCtD
Anagrelide—Gastrointestinal pain—Ramipril—hypertension	1.81e-05	8.52e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—HDAC1—hypertension	1.81e-05	0.000257	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—STK11—hypertension	1.81e-05	0.000257	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX5AP—hypertension	1.81e-05	0.000256	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—hypertension	1.81e-05	0.000256	CbGpPWpGaD
Anagrelide—Nausea—Clonidine—hypertension	1.81e-05	8.51e-05	CcSEcCtD
Anagrelide—Paraesthesia—Lisinopril—hypertension	1.8e-05	8.49e-05	CcSEcCtD
Anagrelide—Vomiting—Captopril—hypertension	1.8e-05	8.49e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—CCL2—hypertension	1.8e-05	0.000255	CbGpPWpGaD
Anagrelide—Dizziness—Hydrochlorothiazide—hypertension	1.8e-05	8.47e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CXCL10—hypertension	1.8e-05	0.000254	CbGpPWpGaD
Anagrelide—Dyspnoea—Lisinopril—hypertension	1.79e-05	8.43e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PLG—hypertension	1.79e-05	0.000254	CbGpPWpGaD
Anagrelide—Rash—Captopril—hypertension	1.79e-05	8.42e-05	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—RHOA—hypertension	1.79e-05	0.000253	CbGpPWpGaD
Anagrelide—Dermatitis—Captopril—hypertension	1.79e-05	8.41e-05	CcSEcCtD
Anagrelide—Somnolence—Lisinopril—hypertension	1.79e-05	8.4e-05	CcSEcCtD
Anagrelide—Feeling abnormal—Timolol—hypertension	1.79e-05	8.4e-05	CcSEcCtD
Anagrelide—Headache—Captopril—hypertension	1.78e-05	8.36e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—AKT2—hypertension	1.77e-05	0.000251	CbGpPWpGaD
Anagrelide—Gastrointestinal pain—Timolol—hypertension	1.77e-05	8.33e-05	CcSEcCtD
Anagrelide—Dizziness—Furosemide—hypertension	1.77e-05	8.33e-05	CcSEcCtD
Anagrelide—PDE3A—GPCR downstream signaling—PIK3R1—hypertension	1.77e-05	0.000251	CbGpPWpGaD
Anagrelide—Dyspepsia—Lisinopril—hypertension	1.77e-05	8.32e-05	CcSEcCtD
Anagrelide—Diarrhoea—Losartan—hypertension	1.77e-05	8.32e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LHB—hypertension	1.77e-05	0.00025	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HADHA—hypertension	1.77e-05	0.00025	CbGpPWpGaD
Anagrelide—Nausea—Trandolapril—hypertension	1.76e-05	8.3e-05	CcSEcCtD
Anagrelide—Urticaria—Ramipril—hypertension	1.76e-05	8.28e-05	CcSEcCtD
Anagrelide—Nausea—Enalapril—hypertension	1.76e-05	8.27e-05	CcSEcCtD
Anagrelide—Dizziness—Betaxolol—hypertension	1.75e-05	8.25e-05	CcSEcCtD
Anagrelide—Vomiting—Perindopril—hypertension	1.75e-05	8.24e-05	CcSEcCtD
Anagrelide—Abdominal pain—Ramipril—hypertension	1.75e-05	8.24e-05	CcSEcCtD
Anagrelide—Body temperature increased—Ramipril—hypertension	1.75e-05	8.24e-05	CcSEcCtD
Anagrelide—Decreased appetite—Lisinopril—hypertension	1.75e-05	8.22e-05	CcSEcCtD
Anagrelide—Vomiting—Irbesartan—hypertension	1.75e-05	8.21e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ADRB2—hypertension	1.74e-05	0.000247	CbGpPWpGaD
Anagrelide—Rash—Perindopril—hypertension	1.74e-05	8.17e-05	CcSEcCtD
Anagrelide—Dermatitis—Perindopril—hypertension	1.74e-05	8.16e-05	CcSEcCtD
Anagrelide—Gastrointestinal disorder—Lisinopril—hypertension	1.74e-05	8.16e-05	CcSEcCtD
Anagrelide—Nausea—Telmisartan—hypertension	1.73e-05	8.15e-05	CcSEcCtD
Anagrelide—Fatigue—Lisinopril—hypertension	1.73e-05	8.15e-05	CcSEcCtD
Anagrelide—Vomiting—Hydrochlorothiazide—hypertension	1.73e-05	8.14e-05	CcSEcCtD
Anagrelide—Rash—Irbesartan—hypertension	1.73e-05	8.14e-05	CcSEcCtD
Anagrelide—Dermatitis—Irbesartan—hypertension	1.73e-05	8.14e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HSD3B2—hypertension	1.73e-05	0.000245	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LPA—hypertension	1.73e-05	0.000245	CbGpPWpGaD
Anagrelide—Headache—Perindopril—hypertension	1.73e-05	8.12e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PRKCE—hypertension	1.72e-05	0.000244	CbGpPWpGaD
Anagrelide—Urticaria—Timolol—hypertension	1.72e-05	8.09e-05	CcSEcCtD
Anagrelide—Headache—Irbesartan—hypertension	1.72e-05	8.09e-05	CcSEcCtD
Anagrelide—Pain—Lisinopril—hypertension	1.72e-05	8.08e-05	CcSEcCtD
Anagrelide—Constipation—Lisinopril—hypertension	1.72e-05	8.08e-05	CcSEcCtD
Anagrelide—Rash—Hydrochlorothiazide—hypertension	1.72e-05	8.08e-05	CcSEcCtD
Anagrelide—Dermatitis—Hydrochlorothiazide—hypertension	1.72e-05	8.07e-05	CcSEcCtD
Anagrelide—Abdominal pain—Timolol—hypertension	1.71e-05	8.05e-05	CcSEcCtD
Anagrelide—Body temperature increased—Timolol—hypertension	1.71e-05	8.05e-05	CcSEcCtD
Anagrelide—Dizziness—Losartan—hypertension	1.71e-05	8.04e-05	CcSEcCtD
Anagrelide—Headache—Hydrochlorothiazide—hypertension	1.71e-05	8.02e-05	CcSEcCtD
Anagrelide—Vomiting—Furosemide—hypertension	1.7e-05	8.01e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PDGFA—hypertension	1.7e-05	0.000241	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VAV3—hypertension	1.7e-05	0.000241	CbGpPWpGaD
Anagrelide—Rash—Furosemide—hypertension	1.69e-05	7.94e-05	CcSEcCtD
Anagrelide—Dermatitis—Furosemide—hypertension	1.69e-05	7.94e-05	CcSEcCtD
Anagrelide—Vomiting—Betaxolol—hypertension	1.69e-05	7.93e-05	CcSEcCtD
Anagrelide—Nausea—Captopril—hypertension	1.69e-05	7.93e-05	CcSEcCtD
Anagrelide—Headache—Furosemide—hypertension	1.68e-05	7.89e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—TGFBR2—hypertension	1.68e-05	0.000237	CbGpPWpGaD
Anagrelide—Rash—Betaxolol—hypertension	1.67e-05	7.86e-05	CcSEcCtD
Anagrelide—Dermatitis—Betaxolol—hypertension	1.67e-05	7.86e-05	CcSEcCtD
Anagrelide—Headache—Betaxolol—hypertension	1.66e-05	7.81e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—GNB3—hypertension	1.66e-05	0.000235	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LRP2—hypertension	1.66e-05	0.000235	CbGpPWpGaD
Anagrelide—Feeling abnormal—Lisinopril—hypertension	1.66e-05	7.79e-05	CcSEcCtD
Anagrelide—Gastrointestinal pain—Lisinopril—hypertension	1.64e-05	7.73e-05	CcSEcCtD
Anagrelide—Vomiting—Losartan—hypertension	1.64e-05	7.73e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—AVP—hypertension	1.64e-05	0.000232	CbGpPWpGaD
Anagrelide—Nausea—Perindopril—hypertension	1.64e-05	7.7e-05	CcSEcCtD
Anagrelide—Nausea—Irbesartan—hypertension	1.63e-05	7.67e-05	CcSEcCtD
Anagrelide—Rash—Losartan—hypertension	1.63e-05	7.66e-05	CcSEcCtD
Anagrelide—Dermatitis—Losartan—hypertension	1.63e-05	7.66e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling by GPCR—RHOA—hypertension	1.62e-05	0.00023	CbGpPWpGaD
Anagrelide—Headache—Losartan—hypertension	1.62e-05	7.61e-05	CcSEcCtD
Anagrelide—Nausea—Hydrochlorothiazide—hypertension	1.62e-05	7.61e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—GNAS—hypertension	1.62e-05	0.000229	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—PIK3R1—hypertension	1.61e-05	0.000228	CbGpPWpGaD
Anagrelide—Urticaria—Lisinopril—hypertension	1.6e-05	7.51e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—hypertension	1.59e-05	0.000226	CbGpPWpGaD
Anagrelide—Nausea—Furosemide—hypertension	1.59e-05	7.48e-05	CcSEcCtD
Anagrelide—Asthenia—Ramipril—hypertension	1.59e-05	7.48e-05	CcSEcCtD
Anagrelide—Body temperature increased—Lisinopril—hypertension	1.59e-05	7.47e-05	CcSEcCtD
Anagrelide—Abdominal pain—Lisinopril—hypertension	1.59e-05	7.47e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—APOB—hypertension	1.58e-05	0.000224	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTK2—hypertension	1.58e-05	0.000223	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—QDPR—hypertension	1.58e-05	0.000223	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HAS3—hypertension	1.58e-05	0.000223	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HAS2—hypertension	1.58e-05	0.000223	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HYAL2—hypertension	1.58e-05	0.000223	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PNMT—hypertension	1.58e-05	0.000223	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HAS1—hypertension	1.58e-05	0.000223	CbGpPWpGaD
Anagrelide—Nausea—Betaxolol—hypertension	1.58e-05	7.41e-05	CcSEcCtD
Anagrelide—CYP1A2—Biological oxidations—POMC—hypertension	1.57e-05	0.000222	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—CXCL8—hypertension	1.57e-05	0.000222	CbGpPWpGaD
Anagrelide—Pruritus—Ramipril—hypertension	1.57e-05	7.37e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—EDN1—hypertension	1.56e-05	0.000221	CbGpPWpGaD
Anagrelide—Asthenia—Timolol—hypertension	1.55e-05	7.31e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CCL5—hypertension	1.55e-05	0.000219	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALOX5—hypertension	1.54e-05	0.000218	CbGpPWpGaD
Anagrelide—Nausea—Losartan—hypertension	1.54e-05	7.22e-05	CcSEcCtD
Anagrelide—Pruritus—Timolol—hypertension	1.53e-05	7.21e-05	CcSEcCtD
Anagrelide—PDE3A—Hemostasis—TP53—hypertension	1.52e-05	0.000216	CbGpPWpGaD
Anagrelide—Diarrhoea—Ramipril—hypertension	1.52e-05	7.13e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—LPL—hypertension	1.51e-05	0.000214	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—H2AFX—hypertension	1.5e-05	0.000213	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RPS6KB1—hypertension	1.5e-05	0.000212	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PDGFRB—hypertension	1.5e-05	0.000212	CbGpPWpGaD
Anagrelide—Diarrhoea—Timolol—hypertension	1.48e-05	6.97e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism—GSTA5—hypertension	1.48e-05	0.00021	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—ADCY5—hypertension	1.48e-05	0.00021	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCG—hypertension	1.47e-05	0.000208	CbGpPWpGaD
Anagrelide—Dizziness—Ramipril—hypertension	1.47e-05	6.89e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—ITGB3—hypertension	1.46e-05	0.000207	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCA—hypertension	1.46e-05	0.000207	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—YWHAZ—hypertension	1.45e-05	0.000205	CbGpPWpGaD
Anagrelide—Asthenia—Lisinopril—hypertension	1.44e-05	6.78e-05	CcSEcCtD
Anagrelide—Dizziness—Timolol—hypertension	1.43e-05	6.74e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—SPP1—hypertension	1.43e-05	0.000203	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NGF—hypertension	1.43e-05	0.000203	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—CXCL8—hypertension	1.43e-05	0.000202	CbGpPWpGaD
Anagrelide—Pruritus—Lisinopril—hypertension	1.42e-05	6.69e-05	CcSEcCtD
Anagrelide—Vomiting—Ramipril—hypertension	1.41e-05	6.63e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism—MDH1—hypertension	1.4e-05	0.000199	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTT2—hypertension	1.4e-05	0.000199	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HYAL1—hypertension	1.4e-05	0.000199	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CDO1—hypertension	1.4e-05	0.000199	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CPS1—hypertension	1.4e-05	0.000199	CbGpPWpGaD
Anagrelide—Rash—Ramipril—hypertension	1.4e-05	6.57e-05	CcSEcCtD
Anagrelide—Dermatitis—Ramipril—hypertension	1.4e-05	6.57e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CCR5—hypertension	1.39e-05	0.000197	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCD—hypertension	1.39e-05	0.000197	CbGpPWpGaD
Anagrelide—Headache—Ramipril—hypertension	1.39e-05	6.53e-05	CcSEcCtD
Anagrelide—Vomiting—Timolol—hypertension	1.38e-05	6.48e-05	CcSEcCtD
Anagrelide—Diarrhoea—Lisinopril—hypertension	1.38e-05	6.47e-05	CcSEcCtD
Anagrelide—Rash—Timolol—hypertension	1.37e-05	6.42e-05	CcSEcCtD
Anagrelide—Dermatitis—Timolol—hypertension	1.36e-05	6.42e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—hypertension	1.36e-05	0.000193	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—HTR2A—hypertension	1.36e-05	0.000193	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—C3—hypertension	1.36e-05	0.000193	CbGpPWpGaD
Anagrelide—Headache—Timolol—hypertension	1.36e-05	6.38e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism—GCH1—hypertension	1.34e-05	0.00019	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP4F12—hypertension	1.34e-05	0.00019	CbGpPWpGaD
Anagrelide—Dizziness—Lisinopril—hypertension	1.33e-05	6.25e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—PDGFB—hypertension	1.33e-05	0.000188	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CETP—hypertension	1.32e-05	0.000188	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGFR1—hypertension	1.32e-05	0.000187	CbGpPWpGaD
Anagrelide—Nausea—Ramipril—hypertension	1.32e-05	6.19e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—HIF1A—hypertension	1.3e-05	0.000184	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AGT—hypertension	1.29e-05	0.000183	CbGpPWpGaD
Anagrelide—PDE3A—Hemostasis—AKT1—hypertension	1.29e-05	0.000182	CbGpPWpGaD
Anagrelide—Nausea—Timolol—hypertension	1.29e-05	6.05e-05	CcSEcCtD
Anagrelide—CYP1A2—Metabolism—PLCD1—hypertension	1.28e-05	0.000182	CbGpPWpGaD
Anagrelide—Vomiting—Lisinopril—hypertension	1.28e-05	6.01e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CALM1—hypertension	1.27e-05	0.00018	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP17A1—hypertension	1.27e-05	0.00018	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—LEP—hypertension	1.27e-05	0.00018	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOE—hypertension	1.27e-05	0.00018	CbGpPWpGaD
Anagrelide—Rash—Lisinopril—hypertension	1.27e-05	5.96e-05	CcSEcCtD
Anagrelide—Dermatitis—Lisinopril—hypertension	1.27e-05	5.95e-05	CcSEcCtD
Anagrelide—Headache—Lisinopril—hypertension	1.26e-05	5.92e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—CAV1—hypertension	1.26e-05	0.000178	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—hypertension	1.26e-05	0.000178	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—APOA1—hypertension	1.25e-05	0.000177	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—KDR—hypertension	1.24e-05	0.000176	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP11B1—hypertension	1.24e-05	0.000175	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AHCY—hypertension	1.24e-05	0.000175	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—hypertension	1.21e-05	0.000171	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—HMGCR—hypertension	1.2e-05	0.00017	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FN1—hypertension	1.2e-05	0.000169	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PRKCB—hypertension	1.2e-05	0.000169	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—F2—hypertension	1.2e-05	0.000169	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—EPHX2—hypertension	1.19e-05	0.000169	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GBA—hypertension	1.19e-05	0.000169	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—DBH—hypertension	1.19e-05	0.000169	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALOX12—hypertension	1.19e-05	0.000169	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM5—hypertension	1.19e-05	0.000169	CbGpPWpGaD
Anagrelide—Nausea—Lisinopril—hypertension	1.19e-05	5.61e-05	CcSEcCtD
Anagrelide—PDE3A—Signaling Pathways—NOTCH1—hypertension	1.17e-05	0.000166	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2J2—hypertension	1.16e-05	0.000164	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—COX5B—hypertension	1.12e-05	0.000159	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ARG1—hypertension	1.12e-05	0.000159	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GLS2—hypertension	1.12e-05	0.000159	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—DECR1—hypertension	1.12e-05	0.000159	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—POMC—hypertension	1.09e-05	0.000154	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—INS—hypertension	1.08e-05	0.000153	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CCL2—hypertension	1.07e-05	0.000151	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALAD—hypertension	1.06e-05	0.000151	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IGF1—hypertension	1.05e-05	0.000148	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT2—hypertension	1.05e-05	0.000148	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—EGFR—hypertension	1.04e-05	0.000148	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PLCE1—hypertension	1.02e-05	0.000144	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—STS—hypertension	1.02e-05	0.000144	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDH7A1—hypertension	1.02e-05	0.000144	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—hypertension	1e-05	0.000142	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SERPINE1—hypertension	9.95e-06	0.000141	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP4A11—hypertension	9.73e-06	0.000138	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ARG2—hypertension	9.73e-06	0.000138	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CBS—hypertension	9.73e-06	0.000138	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—FGF2—hypertension	9.63e-06	0.000136	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RHOA—hypertension	9.59e-06	0.000136	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—XDH—hypertension	9.55e-06	0.000135	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—NOS3—hypertension	9.5e-06	0.000134	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PIK3R1—hypertension	9.5e-06	0.000134	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP3A5—hypertension	9.37e-06	0.000133	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC5A2—hypertension	9.37e-06	0.000133	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGIS—hypertension	9.37e-06	0.000133	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1A—hypertension	9.2e-06	0.00013	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UCP2—hypertension	9.05e-06	0.000128	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TPH1—hypertension	9.05e-06	0.000128	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD11B1—hypertension	9.05e-06	0.000128	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—UCP3—hypertension	9.05e-06	0.000128	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ABCC1—hypertension	9.05e-06	0.000128	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—RELA—hypertension	8.94e-06	0.000127	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOB—hypertension	8.77e-06	0.000124	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MTOR—hypertension	8.77e-06	0.000124	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALAS1—hypertension	8.76e-06	0.000124	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC2A3—hypertension	8.76e-06	0.000124	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP11B2—hypertension	8.76e-06	0.000124	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD3B1—hypertension	8.63e-06	0.000122	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADA—hypertension	8.63e-06	0.000122	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AQP1—hypertension	8.51e-06	0.00012	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—FADS1—hypertension	8.51e-06	0.00012	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CXCL8—hypertension	8.42e-06	0.000119	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—hypertension	8.38e-06	0.000119	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CA9—hypertension	8.28e-06	0.000117	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TBXAS1—hypertension	8.28e-06	0.000117	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—hypertension	8.17e-06	0.000116	CbGpPWpGaD
Anagrelide—PDE3A—GPCR downstream signaling—AKT1—hypertension	8.14e-06	0.000115	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—hypertension	8.09e-06	0.000115	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALOX15—hypertension	8.07e-06	0.000114	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALOX5AP—hypertension	8.07e-06	0.000114	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—IL6—hypertension	8.01e-06	0.000113	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CD36—hypertension	7.96e-06	0.000113	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LHB—hypertension	7.87e-06	0.000111	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HADHA—hypertension	7.87e-06	0.000111	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—KCNJ11—hypertension	7.69e-06	0.000109	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSD3B2—hypertension	7.69e-06	0.000109	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LPA—hypertension	7.69e-06	0.000109	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MMP9—hypertension	7.62e-06	0.000108	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—CDKN1A—hypertension	7.59e-06	0.000108	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—PTEN—hypertension	7.57e-06	0.000107	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MAPK8—hypertension	7.41e-06	0.000105	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—hypertension	7.4e-06	0.000105	CbGpPWpGaD
Anagrelide—PDE3A—Signaling by GPCR—AKT1—hypertension	7.39e-06	0.000105	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LRP2—hypertension	7.38e-06	0.000104	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP2C18—hypertension	7.38e-06	0.000104	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EP300—hypertension	7.22e-06	0.000102	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—hypertension	7.17e-06	0.000101	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HSPG2—hypertension	7.1e-06	0.000101	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—SRC—hypertension	7.02e-06	9.95e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—hypertension	7.02e-06	9.94e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—hypertension	6.96e-06	9.85e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—hypertension	6.94e-06	9.83e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALOX5—hypertension	6.86e-06	9.71e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GLP1R—hypertension	6.86e-06	9.71e-05	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—VEGFA—hypertension	6.84e-06	9.69e-05	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—MYC—hypertension	6.29e-06	8.91e-05	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TGFB1—hypertension	6.28e-06	8.89e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALDH2—hypertension	6.27e-06	8.88e-05	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—EGFR—hypertension	6.16e-06	8.72e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—hypertension	6.12e-06	8.66e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HBA1—hypertension	6.11e-06	8.66e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP11A1—hypertension	6.07e-06	8.6e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—hypertension	6.03e-06	8.54e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC9A1—hypertension	5.97e-06	8.45e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTT1—hypertension	5.97e-06	8.45e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GCLC—hypertension	5.9e-06	8.35e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CETP—hypertension	5.9e-06	8.35e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP17A1—hypertension	5.65e-06	8e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ENO1—hypertension	5.59e-06	7.92e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS1—hypertension	5.59e-06	7.92e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hypertension	5.5e-06	7.79e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CTGF—hypertension	5.38e-06	7.62e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMGCR—hypertension	5.33e-06	7.55e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GOT2—hypertension	5.33e-06	7.55e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3R1—hypertension	5.26e-06	7.45e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADRA2A—hypertension	5.22e-06	7.39e-05	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—TP53—hypertension	5.17e-06	7.32e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—TH—hypertension	4.89e-06	6.92e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CALM2—hypertension	4.87e-06	6.9e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—hypertension	4.81e-06	6.81e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GCG—hypertension	4.75e-06	6.73e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—SLC2A4—hypertension	4.75e-06	6.73e-05	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—IL6—hypertension	4.73e-06	6.7e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GOT1—hypertension	4.6e-06	6.52e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP19A1—hypertension	4.47e-06	6.33e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—STK11—hypertension	4.47e-06	6.33e-05	CbGpPWpGaD
Anagrelide—PDE3A—Signaling Pathways—AKT1—hypertension	4.36e-06	6.18e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hypertension	4.2e-06	5.94e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—COMT—hypertension	4.15e-06	5.88e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARGC1A—hypertension	4.1e-06	5.8e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GNB3—hypertension	4.1e-06	5.8e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—HMOX1—hypertension	4.08e-06	5.78e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CAT—hypertension	4.02e-06	5.7e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hypertension	4e-06	5.67e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GNAS—hypertension	3.99e-06	5.65e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOB—hypertension	3.91e-06	5.53e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GSTM1—hypertension	3.8e-06	5.38e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—LPL—hypertension	3.73e-06	5.28e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ADCY5—hypertension	3.65e-06	5.17e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—GPX1—hypertension	3.64e-06	5.15e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PRKCA—hypertension	3.6e-06	5.1e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CYP1A1—hypertension	3.6e-06	5.1e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CD36—hypertension	3.54e-06	5.02e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—MTHFR—hypertension	3.36e-06	4.76e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARA—hypertension	3.29e-06	4.67e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AGT—hypertension	3.19e-06	4.52e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CALM1—hypertension	3.14e-06	4.44e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOE—hypertension	3.13e-06	4.43e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—CAV1—hypertension	3.1e-06	4.39e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—APOA1—hypertension	3.09e-06	4.38e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PPARG—hypertension	2.72e-06	3.86e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—POMC—hypertension	2.69e-06	3.8e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—INS—hypertension	2.67e-06	3.78e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—ALB—hypertension	2.45e-06	3.47e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PIK3R1—hypertension	2.34e-06	3.32e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—NOS3—hypertension	2.34e-06	3.32e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTGS2—hypertension	2.14e-06	3.03e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—PTEN—hypertension	1.87e-06	2.65e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—EP300—hypertension	1.78e-06	2.52e-05	CbGpPWpGaD
Anagrelide—CYP1A2—Metabolism—AKT1—hypertension	1.08e-06	1.52e-05	CbGpPWpGaD
